Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial

被引:194
|
作者
Grotta, JC
Welch, KMA
Fagan, SC
Lu, M
Frankel, MR
Brott, T
Levine, SR
Lyden, PD
机构
[1] Univ Texas, Sch Med, Dept Neurol, Stroke Program, Houston, TX 77030 USA
[2] Henry Ford Hlth Sci Ctr, Dept Biostat & Res Epidemiol, Detroit, MI USA
[3] Henry Ford Hlth Sci Ctr, Dept Pharm Serv, Detroit, MI USA
[4] Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA
[5] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA
[6] Univ Cincinnati, Sch Med, Dept Neurol, Cincinnati, OH USA
[7] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA
[8] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA
关键词
deterioration; reocclusion; stroke; thrombolysis;
D O I
10.1161/01.STR.32.3.661
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Little is known in regard to cerebral arterial reocclusion after successful thrombolysis. In the absence of arteriographic information, the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial investigators prospectively identified clinical deterioration following improvement (DFI) as a possible surrogate marker of cerebral arterial reocclusion after rt-PA-induced recanalization. Also, we identified any significant clinical deterioration (CD) even if not preceded by improvement. This observational analysis was designed to determine the incidence of DFI and CD in each treatment group, to identify baseline or posttreatment variables predictive of DFI or CD, and to determine any relationship between DFI, CD, and clinical outcome. Methods-DFI was defined as any 2-point deterioration on the NIH Stroke Scale after an initial 2-point improvement after treatment. CD was defined as any 4-point worsening after treatment compared with baseline. All data were collected prospectively by investigators blinded to treatment allocation. A noncontrast brain CT was mandated when a 2-point deterioration occurred. All cases were validated by a central review committee. Results-DFI was identified in 81 of the 624 patients (13%); 44 were treated with rt-PA and 37 were treated with placebo (P=0.48). DFI occurred more often in patients with a higher baseline NIH Stroke Scale score. CD within the first 24 hours occurred in 98 patients (16% of all patients); 43 were given rt-PA and 55 were given placebo (P=0.19). Baseline variables associated with CD included a less frequent use of prestroke aspirin and a higher incidence of early CT changes of edema or mass effect or dense middle cerebral artery sign. Patients with CD had higher rates of increased serum glucose and fibrin degradation products, and they also had higher rates of symptomatic intracranial hemorrhage and death. Patients who experienced either DFT or CD were less likely to have a 3-month favorable outcome. Conclusions-We found no association between DFI, CD, and rt-PA treatment, and no clinical evidence to suggest reocclusion. Deterioration was strongly associated with stroke severity and poor outcome and was less frequent in patients whose stroke occurred while they were on aspirin.
引用
收藏
页码:661 / 668
页数:8
相关论文
共 50 条
  • [41] Augmented Treatment Efficacy - A Repeated Measures Analysis of NINDS rt-PA Study
    Feng, Wuwei
    Vasquez, Gabriela
    Suri, Muhammad Fareed
    Lakshminarayan, Kamakshi
    Qureshi, Qureshi
    NEUROLOGY, 2010, 74 (09) : A342 - A342
  • [42] Hyperdense Ischemic Infarcts in the NINDS rt-PA Trials Reflect Hyperglycemia, Not Hemorrhage
    Liebeskind, David S.
    Levine, Steven R.
    Wang, He-Jing
    Patel, Suresh C.
    STROKE, 2009, 40 (04) : E117 - E117
  • [43] Role of rt-pa on bdnf metabolism in stroke
    Rodier, M.
    Mossiat, C.
    Marie, C.
    Garnier, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 : 84 - 85
  • [44] Successful use of rt-PA in pediatric stroke
    Carlson, MD
    Leber, S
    Deveikis, J
    Silverstein, FS
    NEUROLOGY, 2001, 57 (01) : 157 - 158
  • [45] A Matched Comparison of Eptifibatide Plus rt-PA Versus rt-PA Alone in Acute Ischemic Stroke
    Adeoye, Opeolu
    Knight, William A.
    Khoury, Jane
    Schmit, Pamela A.
    Sucharew, Heidi
    Broderick, Joseph P.
    Pancioli, Arthur M.
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2014, 23 (05): : E313 - E315
  • [47] Review, Historical Context, and Clarifications of the NINDS rt-PA Stroke Trials Exclusion Criteria Part 1: Rapidly Improving Stroke Symptoms
    Levine, Steven R.
    Khatri, Pooja
    Broderick, Joseph P.
    Grotta, James C.
    Kasner, Scott E.
    Kim, Doojin
    Meyer, Brett C.
    Panagos, Peter
    Romano, Jose
    Scott, Phillip
    STROKE, 2013, 44 (09) : 2500 - 2505
  • [48] Results of clinical trial of intravenous rt-PA (Alteplase) for acute ischemic stroke: Japan Alteplase Clinical Trial (J-ACT)
    Minematsu, K
    Yamaguchi, T
    Hashi, K
    Shinohara, Y
    Saito, I
    Mori, E
    Nakagawara, J
    STROKE, 2004, 35 (06) : E216 - E216
  • [49] Effect of Serum Lipid Levels on Stroke Outcome after rt-PA Therapy: SAMURAI rt-PA Registry
    Makihara, Noriko
    Okada, Yasushi
    Koga, Masatoshi
    Shiokawa, Yoshiaki
    Nakagawara, Jyoji
    Furui, Eisuke
    Kimura, Kazumi
    Yamagami, Hiroshi
    Hasegawa, Yasuhiro
    Kario, Kazuomi
    Okuda, Satoshi
    Naganuma, Masaki
    Toyoda, Kazunori
    CEREBROVASCULAR DISEASES, 2012, 33 (03) : 240 - 247
  • [50] ANALYSIS OF THE CLINICAL EFFICACY AND SAFETY OF RT-PA IN TREATMENT OF ACUTE ISCHEMIC STROKE
    Wu, Junyi
    Zing, Xiaoyun
    Luo, Zhixiu
    Zhou, Jie
    ACTA MEDICA MEDITERRANEA, 2019, 35 (02): : 765 - 769